CCSVI success of angioplasty for venous narrowing

The short version: the balloon usually opens the vein on the table, but the jugulars are back to half-closed within a year and a half.

Technical success and lasting patency are different questions. Opening the narrowing is easy; keeping it open is the problem. In one CCSVI series, 18-month patency was 53% in the internal jugular veins versus 96% in the azygos vein [1]. The azygos holds; the jugulars do not. A four-year follow-up of 366 patients found seven progressive patients developed jugular thrombosis after a second procedure, all in veins that were already underdeveloped before any intervention [2].

The clinical side is thinner than the patency side. The four-year follow-up was uncontrolled, patients chose their own physician, and symptoms were recorded only as present or absent, not scored [2]. Fatigue "improvement" of 98.5% in relapsing-remitting patients [2] is not a credible treatment effect in a self-selected cohort with no comparison group. In progressive patients the same cohort showed 6.5% and 5.0% still improved at 36-48 months [2], which is closer to what you would expect from regression to the mean.

The diagnostic foundation is also shaky. CCSVI prevalence in MS ranges from 56% to 100% depending on the Doppler protocol, and other imaging methods did not replicate the difference [1]. Operator training changes agreement substantially: 0.47 between trained and untrained operators versus 0.80 between trained operators [1]. If the diagnosis itself is unreliable, "success" of treating it is hard to define.

My call: angioplasty reliably opens the vein in the short term, but jugular patency is poor at 18 months, the azygos holds better, and no controlled evidence here shows clinical benefit. Confidence: moderate on patency, low on any clinical benefit.